Topics

Companies Related to "Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain" [Most Relevant Company Matches] RSS

02:49 EDT 19th October 2019 | BioPortfolio

Here are the most relevant search results for "Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain" found in our extensive corporate database of over 50,000 company records.

Showing "Ropivacaine Dexamethasone Lignocaine Injection Block Intractable Cancer Pain" Companies 1–25 of 3,300+

Relevant

JumpStart Inc.

Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing neurostimulation therapies for unmet needs to patients worldwide. The Company's platform technology, Nerve Block, provides patients with elimination of chronic pain and spasticity in a variety of applications including neuroma/residual limb pain with potential applications in cancer pain, diabetic neuropath...


Xenome Limited

Xenome aims to develop new treatments for pain, particularly intractable pain as experienced by many cancer patients, as well as other neurological conditions for which there is an unmet clinical need, e.g stroke.Xenome has an exclusive license to a collection of molecules and related technologies discovered by the Centre for Drug Design and Development (the Centre) at the University of Queensland...

H&R Block Bank

H&R Block is guided by a mission that is understood, embraced and pursued by the entire organization: "To help our clients achieve their financial objectives by serving as their tax and financial partner." As part of the H&R Block family of companies, the H&R Block Bank furthers that corporate mission by offering needed banking products and services that are simple and affordable to our customers....


Angstrom Pharmaceuticals Incorporated

Ångstrom Pharmaceuticals, Inc. was formed in 1996 to add a new dimension to drug discovery. It is committed to discovering drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell – when this event is responsible for initiating a disease state. Receptors can be identified that trigger several intractable diseases including cance...

Winston Pharmaceuticals, Inc.

Winston is a pharmaceutical company focused on pain control which is developing products for large pain control markets, as well as for niche markets, where there are still significant unmet needs for pain management options with improved efficacy, safety, and tolerability profiles. Winston's late stage product candidates include osteo- and rheumatoid arth...

Neuromed

Neuromed is a biopharmaceutical company developing new and improved pain therapies. Lead drug candidate, OROS Hydromorphone®, in Phase 3 clinical development, is an extended release formulation of hydromorphone. In collaboration with Merck, Neuromed is also researching compounds designed to block the N-type calcium channel, a target linked to pain signal transmission. Separately, Neuromed is deve...

Neuromed Pharmaceuticals

Neuromed is a biopharmaceutical company developing new and improved pain therapies. Lead drug candidate, OROS Hydromorphone®, in Phase 3 clinical development, is an extended release formulation of hydromorphone. In collaboration with Merck, Neuromed is also researching compounds designed to block the N-type calcium channel, a target linked to pain signal transmission. Separately, Neuromed is deve...

Dynatronics

A leader in the manufacture and distribution of products for the rehabilitation and aesthetic markets, now Dynatronics introduces a revolutionary breakthrough in the treatment of chronic intractable pain. The Dynatron® STS™ clinical device and the Dynatron® STS Rx™ model for home use offer new hope for the millions of people who suffer daily from chronic pain.Dynatronics also manufactures th...

Ocular Therapeutix™, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular ...

Otonomy, Inc.

Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. The company's core technology is a sustained release formulation developed for optimal delivery of drugs from a single intratympanic (IT) injection. Broad applicability of this delivery and formulation technology has already been established across a number of therapeuti...

Boundless Bio

Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers. For more information, visit www.boundlessbio.com.

CNS Therapeutics

Founded in 2007 by recognized experts in intrathecal drug therapies, CNS Therapeutics is a private company based in St. Paul, Minnesota. CNS Therapeutics develops and markets safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain. In addition to this first FDA-approved pr...

Cytogen

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. Q...

The Rosomoff Comprehensive Pain Center (RCPC)

The Rosomoff Comprehensive Pain Center (RCPC) is a state-of-the-art Center of Excellence offering inpatient, outpatient, outpatient rehabilitation services and seniors programs. Founded in 1974 as the University of Miami Comprehensive and Rehabilitation Center, the Center became an internationally renowned model for the evaluation and treatment of all persons seeking pain relief. We specialize in ...

YM BioSciences Inc

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF™, a p...

Cognetix, Inc.

Cognetix is a private drug discovery and development company located in Salt Lake City, Utah, focused on commercializing conopeptide-based pharmaceuticals. Conopeptides are bioactive peptides in the venom of marine cone snails. The Company is currently in clinical trials investigating its lead compound, CGX-1160, for the treatment of chronic intractable pain. The Company has a strong drug discover...

Techpool Bio-pharma Co., Ltd.

Established in 1993, Techpool Bio-Pharma Co., Ltd. is one of the leading bio-pharma companys in China, with total assets of USD30 million and registered capital of USD11.7 million. We are specializing in R&D, manufacturing and marketing of bio-pharmaceutical products and currently export to Japan, Korea, India, Pakistan, Israel etc. We manufacture the following pharmaceutical products: Finished p...

Kronos Bio, Inc.

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (...

Concentric Analgesics, Inc.

Concentric Analgesics, Inc. is a privately-held, clinical-stage biopharmaceutical company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain. The Company’s core proprietary technology is the foundation of a broad portfolio of patented TRVP1-agonist prodrugs. In addition to its flagship pos...

Syngenix Limited

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery probes such as antisense in vivo for > drug target validation and systems for targeting small drugs and macromolecules to the site of disease. The core platform technologies have been demonstrated by...

National Pain Foundation

The National Pain Foundation (NPF), a non-profit organization, is the premier provider of information, education and support to people with chronic pain. Materials are provided for both patients and medical professionals interested in the field of chronic pain. The NPF aims to empower people in pain by educating them about their condition, providing information about the options available for mana...

Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes ...

Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-re...

Florida Society of Interventional Pain Physicians

FSIPP is a not-for-profit organization whose members promote the development and practice of safe, high quality, cost-effective interventional pain management techniques for the diagnosis and treatment of pain and related disorders. Members are advocates for the health of their patients and uphold the high principles, policies, and practices of their medical specialty. They also pursue to educate ...

Let's Talk Pain Coalition

Episode One: Tackling the Challenges of Pain and Pain Management


More From BioPortfolio on "Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain"

Quick Search

Corporate Database Quicklinks